Translational Neurobiotech Developments Reviewed. Brain Waves: The field of neurotechnology, the focus of this blog, encompasses advances in brain science (neurons), information technology (bits) and bioengineering (genes). Up for discussion and analysis: the political, economic, ethical, and social forces that will shape the future of what will be one of the most important and fascinating stories of the coming decades.

About this author

Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev

Receive by email

GUEST AUTHOR ARCHIVES

In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

« Socialtext Release Commerical Open Source Wiki | Main | Pretty Pearlescent Pills - Colorful Drugs Approved by FDA »

July 24, 2006

Translational Neurobiotech Developments Reviewed

Posted by Zack Lynch

The July edition of Genetic Engineering News published an extensive review of a dozen CEO company presentations from the NeuroInsights' Neurotech Industry Investing conference in May. I recommend following the link to read the full review. Written by Gail Schechter, the article "Translational Medicine: Spotlighting Neurobiotech Developments Central Nervous System Remains a Large Target for Novel Therapies" highlights companies from several panels including: Targacept, Saegis Pharmaceuticals, Acumen Pharmaceuticals, Ceregene, Jazz Pharmaceuticals, Amarin, Predix Pharmaceuticals, BrainCells Inc., NeuroNova, Sound Pharmaceuticals, StemCells Inc., and StemCell Sciences.

116_Neurotech_Industry_Conference_-_May_18%2C_2006_Page_1_sm.jpg Gail concludes, "Conference panelists, presenters, and participants alike were clearly favorably disposed toward neurotechnology, in spite of the unique challenges confronting CNS product development. Representatives from both venture capital and big pharma reported being open to funding neurotechnology, especially when a company’s products have already demonstrated proof-of-concept, are further along in clinical development, and have a clear commercialization path. High-risk is mitigated by the potential for significant reward. After all, today’s risks may be tomorrow’s breakthroughs."

If you missed this year's conference, mark your calendars for next year's two day Neurotech Industry Investing and Business Conference 2007 which will be held in San Francisco on May 17 and 18. If you are interested in speaking or sponsoring please contact me.

Comments (1) + TrackBacks (0) | Category: Neurotech Industry

COMMENTS

1. Grant on July 26, 2006 11:18 PM writes...

"today’s risks may be tomorrow’s breakthroughs", I think a bold but an accurate statement. Without risks there is no stepping forward.

Permalink to Comment

POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)